Bizarre Patents
Neuroimaging as a Marketing Tool
Neuroimaging as a means for validating whether a stimulus such as advertisement, communication, or product evokes a certain mental response such as emotion, preference, or memory, or to predict the consequences of the stimulus on later behavior such as consumption or purchasing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8084585 | Anti-ILT7 antibody An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT fa... | 12/27/2011 |
| 7816500 | Antibody SACK-1 that binds CD44 glycoforms Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. ... | 10/19/2010 |
| 7728115 | Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. ... | 06/01/2010 |
| 7718780 | Preparation of monoclonal antibody to downstream regulated gene 2 and determination of NDRG2 using protein chip The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same.... | 05/18/2010 |
| 7576188 | Antitumoral treatments Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies. ... | 08/18/2009 |
| 7563876 | Human monoclonal antibodies to dendritic cells Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antib... | 07/21/2009 |
| 7517966 | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and ... | 04/14/2009 |
| 7429647 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 09/30/2008 |
| 7425421 | Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a seco... | 09/16/2008 |
| 7425447 | Host cells expressing 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 09/16/2008 |
| 7420039 | Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production o... | 09/02/2008 |
| 7417128 | 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 08/26/2008 |
| 7414123 | Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 08/19/2008 |
| 7411051 | Antibodies to HDPPA04 polypeptide The present invention relates to antibodies that specifically bind HDPPA04 polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said HDPPA04. Also encompassed by the invention are host cells and hybridomas for producing ... | 08/12/2008 |
| 7399471 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 07/15/2008 |
| 7393529 | Methods and compositions for inhibiting binding of IgE to a high affinity receptor The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals. ... | 07/01/2008 |
| 7387776 | Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by underg... | 06/17/2008 |
| 7371382 | Methods of inhibiting αβ-mediated binding with αβ-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αVβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Addit... | 05/13/2008 |
| 7361345 | Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the... | 04/22/2008 |
| 7361344 | Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of remova... | 04/22/2008 |
| 7338660 | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 03/04/2008 |
| 7323170 | Anti-CD80 antibodies The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention... | 01/29/2008 |
| 7309489 | Mouse CD40 ligand-specific antibodies and hybridomas There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding r... | 12/18/2007 |
| 7306800 | Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the b... | 12/11/2007 |
| 7291331 | Methods of treating OX40 medicated recall immune responses T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model... | 11/06/2007 |
| 7288255 | Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases. ... | 10/30/2007 |
| 7288252 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 10/30/2007 |
| 7288251 | Antibodies to CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 10/30/2007 |
| 7271251 | adhesin binding group antigen A novel Helicobacter pylori blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antigens. The protein sequence of said adhesin is disclosed in this... | 09/18/2007 |
| 7262278 | Anti-HLA-DR antibody This invention provides an anti-HLA-DR monoclonal antibody. This invention relates to an antibody binding to HLA-DR or a functional fragment thereof having (a) life-extending effects in nonhuman animals bearing HLA-DR-expressing cancer cells and (b) activity of supp... | 08/28/2007 |
| 7259247 | Anti-human T-cell costimulating polypeptide monoclonal antibodies A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the ... | 08/21/2007 |
| 7247718 | Antibody recognizing a small subset of human hematopoietic cells The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. I... | 07/24/2007 |
| 7238784 | Rh antibody Rh antibody hybrids for use in testing red blood cells for the presence of one or more Rh factors. The Rh hybrid antibody may also be used in therapeutic procedures which require the use of Rh antisera. The hybrid antibody includes an IgG anti-Rh antibody which has ... | 07/03/2007 |
| 7211400 | Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), olig... | 05/01/2007 |
| 7196175 | Antibodies to JTT-1 protein and cells secreting such antibodies Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell ... | 03/27/2007 |
| 7192585 | CD80 specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 03/20/2007 |
| 7193064 | Anti-CD40 monoclonal antibody An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. ... | 03/20/2007 |
| 7183108 | Selection and uses of lactic acid bacteria strains modulating non-specific immunity The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fe... | 02/27/2007 |
| 7175847 | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 02/13/2007 |
| 7172759 | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40. ... | 02/06/2007 |
